Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-15T05:35:36.587Z Has data issue: false hasContentIssue false
  • English
  • Français

Legal and organisational innovation in the Italian pharmacy system: commercial vs public interest

Published online by Cambridge University Press:  26 April 2017

Alceste Santuari
Alceste Santuari*
Affiliation:
Department of Sociology and Business Law, University of Bologna, Piazza Scaravilli, Bologna, Italy
*
*Correspondence to: Alceste Santuari, University of Bologna, Piazza Scaravilli, 1 40126 Bologna, Italy. Email: alceste.santuari@unibo.it
Get access Rights & Permissions [Opens in a new window]

Abstract

Pharmacy services are undoubtedly an important part of primary care. Pharmacists are entrepreneurs and simultaneously they are entrusted with a public mission in the health care sector. Pharmacies then reflect a contrast between a commercial/economic objective and public interest, which is to be identified with citizens’ universal right to health care services. This is the reason why in Italy, as in many other EU countries, pharmacies supply their services according to a prior authorisation granted by public authorities. In common with many EU countries, this authorisation is secured according to a demographic criterion. It is only by means of these licensed pharmacies that citizens can buy drugs under medical prescription. Accordingly, the health system is to be driven by public interest, which has yet to prove how competing interests may be regulated in serving health needs. In the light of EU law, the article advocates for an innovative legal and organisational tool whereby to organise the Italian pharmacy system in order to combine economic consideration and public benefit.

Type
Articles
Information
Health Economics, Policy and Law , Volume 12 , Special Issue 4: SPECIAL ISSUE: Healthcare and Health Innovation in Europe: Regulating for public benefit or for commercial profit? , October 2017 , pp. 495 - 513
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barretta, L. U. (2014), ‘Il diritto alla salute nello spazio europeo: la mobilità sanitaria alla luce della direttiva 2011/24/UE’. 15th October, www.federalismi.it.Google Scholar
Bertarini, B. (2014), ‘Il servizio farmaceutico’, in M. Sesta (ed.), L’erogazione della prestazione medica tra diritto alla salute, principio di autodeterminazione e gestione ottimale delle risorse sanitarie, Rimini: Maggioli Editore, 747–772.Google Scholar
Buttigieg, F. (2009), ‘The European Court of Justice on the liberalisation of community pharmacy services’, Journal of the Malta College of Pharmacy Practice, 15: 41–42.Google Scholar
Caldirola, D. (2014), ‘Welfare State tra sovranità e vincoli di bilancio: ricadute sul principio di sussidiarietà’, 26 November, www.federalismi.it [2 June 2016].Google Scholar
Chico, V., Hervey, T., Stirton, R. and Warren-Jones, A. (2014), ‘Editorial, Markets and Vulnerable Patients: Health Law After The 2012 Act’, Medical Law Review, 22(2): 157–161.CrossRefGoogle ScholarPubMed
Constitutional Reform Act (2011), 18 October 2011, No. 3.Google Scholar
Council of the EU (2013), ‘Council Conclusions on the Reflection Process on Modern, Responsive and Sustainable Health Systems’, European Commission, Brussels, http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/140004.pdf [20 April 2015].Google Scholar
Council of the EU (2016), ‘Council Conclusions on Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States’, European Commission, Brussels, 17 June.Google Scholar
Den Exter, A. and Guy, M. (2014), ‘Market competition in healthcare markets in the Netherlands: some lessons for England?’ Medical Law Review, 22(2): 255–273.CrossRefGoogle ScholarPubMed
Denicolò, V. (2004), ‘L’attività dell’Autorità garante per la concorrenza e il mercato nel settore farmaceutico’, in G. Fiorentini (ed.), I servizi sanitari in Italia, Bologna: il Mulino, 285–311.Google Scholar
Diverio, D. (2014), ‘Interessi economici e tutela della salute: il caso (ir)risolto delle parafarmacie’, Diritto Pubblico Comparato Europeo – II, Mercato, concorrenza e politiche sociali, 904–913 Google Scholar
ECJ.Google Scholar
Delattre (1991) ‘Criminal Proceedings Against Jean-Marie Delattre’, [1991] E.C.R. 1-1487, [1993] 2C.M.L.R 445.Google Scholar
C-322/01, Deutscher Apothekerverband EV, 11 December 2003.Google Scholar
C-531/06, Commission/Italian Republic, ECJ, 19 May 2009.Google Scholar
C-171/07 and C-172/07, Apothekerkammer des Saarlandes, 19 May 2009.Google Scholar
C-570/07 and C-571/07, Blanco Pérez, ECJ, 1 June 2010.Google Scholar
C-563/08, Carlos Sàez Sanchez (Spain), ECJ, 6 October 2010.Google Scholar
C-217/09, Maurizio Polisseni and others, ECJ, 17 December 2010.Google Scholar
C-315/08, Angelo Grisoli v Regione Lombardia (Italy), 29 September 2011.Google Scholar
C-159/12 through C-161/12, ECJ, 5 December 2013.Google Scholar
C-367/12, Sokoll-Seebacher (Austria), ECJ, 13 February 2014.Google Scholar
C-497/12, Gullotta and Farmacia di Gullotta Davide & C., 2 July 2015.Google Scholar
C-634/15, Sokoll‑Seebacher and Manfred Naderhirn, 30 June 2016.Google Scholar
European Commission, ‘A single market for the 21 st century Europe’, {COM(2007) 724 final} {SEC(2007) 1514} {SEC(2007) 1515} {SEC(2007) 1516}, para 4, p. 9.Google Scholar
European Commission, ‘First Biennial Report on Social Services of General Interest’, COM(2008) 418 final.Google Scholar
European Commission, ‘Proposal for a Regulation of the European Parliament and of the Council on Establishing a Health for Growth Programme, The Third Multi-Annual Programme of EU Action in the Field of Health for the Period 2014-2020’, Brussels, 9 November 2011, COM(2011) 709 final 2011/0339(COD).Google Scholar
European Commission, ‘Effective, Accessible and Resilient Health Systems’, Brussels, 4 April 2014, COM(2014) 215 final.Google Scholar
Ghidini, C. (2016), ‘La “mancata” liberalizzazione dei farmaci di fascia c): la voce della concorrenza’, dimt.it [3 June 2016].Google Scholar
Gibson, S. G. and Lemmens, T. (2014), ‘Niche markets and evidence assessment in transition: a critical review of proposed drug reforms’, Medical Law Review, 22(2): 200–220.CrossRefGoogle ScholarPubMed
Golino, C. (2013), Il principio del pareggio di bilancio, Padua: Cedam.Google Scholar
Gorecki, P. K. (2011), ‘Do you believe in magic? Improving the quality of pharmacy services through restricting entry and aspirational contracts, the Irish experience’, European Journal of Health Economics, 12: 521–531.CrossRefGoogle Scholar
Gormley, L. W. (1995), ‘Two years after Keck’, Fordham International Law Journal, 19(3): 3.Google Scholar
Italian Competition Authority (1997), ‘Official Bulletin No. 40’, p. 74.Google Scholar
Italian Competition Authority (1998), ‘Recommendation No. AS144, “Regulation of Pharmacies”, Official Bulletin No. 23’, www.agcm.it [10 June 2016].Google Scholar
Italian Supreme Administrative Court.Google Scholar
Decision of 4 October 2016, No. 4085.Google Scholar
Italian Supreme Court.Google Scholar
Decision of 18 October 1983, No. 312.Google Scholar
Decision of 12 January 1996, No.4.Google Scholar
Decision of 10 March 2006, No. 87.Google Scholar
Decision of 28 December 2006, No. 448.CrossRefGoogle Scholar
Decision of 14 December 2007, No. 430.CrossRefGoogle Scholar
Decision of 28 March 2008, No. 76.Google Scholar
Decision of 13 November 2009, No. 295.Google Scholar
Decision of 18 July 2014, No. 216.CrossRefGoogle Scholar
Levaggi, R. and Capri, S. (2013), Economia Sanitaria, Rome: Franco Angeli.Google Scholar
Lluch, M. (2009), ‘Are regulations of community pharmacies in Europe questioning our pro-competitive policies?’ Eurohealth, 15(4).Google Scholar
Lluch, M. and Kanavos, P. (2010), ‘Impact of regulation of community pharmacies on efficiency, access and equity. Evidence from the UK and Spain’, Health Policy, 95: 245–254.CrossRefGoogle ScholarPubMed
Martins, S. F., Foppe van Mil, J. W. and Alves da Costa, F. (2015), ‘The organizational framework of community pharmacies in Europe’, International Journal of Clinical Pharmacy, 37: 896–905.CrossRefGoogle ScholarPubMed
Mastragostino, F. (2006), ‘La disciplina delle farmacie comunali’, in D. de Pretis (ed.), La gestione delle farmacie comunali: modelli e problemi giuridici, University of Trento – Dipartimento di Scienze Giuridiche, Trento, 5–25.Google Scholar
Műller-Armack, A. (1990), ‘Wirtschaftslenkung und Marktwirtschaft (1946)’, Munich.Google Scholar
Newdick, C. (2008), ‘Preserving social citizenship in health care markets: there may be trouble ahead’, Mcgill Journal of law and health / Revue de droit et santé de Mcgill, 2: 93–108.Google Scholar
Noyce, P. R. (2007), ‘Providing patient care through community pharmacies in the UK: policy, practice, and research’, The Annals of Pharmacotherapy, 41: 861–868.CrossRefGoogle ScholarPubMed
Paterson, I, Fink, M., Ogus, A., Merz, J., Fink, F., Berrer, H. (2003), ‘Economic Impact of Regulation in the Field of Liberal Professions in Different Member States’, Final Report – Part 1, Study for the European Commission, Institute for Advanced Studies (HIS), Vienne.Google Scholar
Petretto, A. (2011), ‘Modelli economici di organizzazione e finanziamento’, in E. Catelani, G. Cerrina Ferona and M. C. Grisolia (eds), Diritto alla salute tra uniformità e differenziazione, Turin: Modelli di organizzazione sanitaria a confronto, 83–109.Google Scholar
Philipsen, N. (2003), ‘Regulation of and by Pharmacists in the Netherlands and Belgium. An Economic Approach’, Intersentia, Antwerp.Google Scholar
Salerno, N. C. (2014), ‘La Corte Costituzionale e le Farmacie’, 18 September, www.reforming.it [10 June 2016].Google Scholar
Sunstein, C. R. (2014), Why Nudge. The Politics of Libertarian Paternalism, New Haven & London: Yale University Press.Google Scholar
Vogler, S. (2014), ‘Competition Issues in the Distribution of Pharmaceuticals’, OECD, Global Forum on Competition, Paris 18 March.Google Scholar
Vogler, S., Arts, D. and Sandberger, K. (2012), ‘Impact of Pharmacy Deregulation and Regulation in European Countries’, Summary Report, Gesundheit Oesterreich, Vienna.Google Scholar
Vogler, S., Habimana, K. and Arts, D. (2014), ‘Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries’, Health Policy, 117: 311–327.CrossRefGoogle ScholarPubMed
Urbani Neri, F. (2013), ‘Note minime sulla vendita dei farmaci di fascia C nelle parafarmacie’, Rassegna Avvocatura dello Stato, 4. Section 01, 38–50.Google Scholar